(Q34138857)

31 July 2017

title

Developments in nonsteroidal antiandrogens targeting the androgen receptor (English)

1 reference

31 July 2017

Bo Liu

1

1 reference

31 July 2017

Lei Su

2

1 reference

31 July 2017

Jingkun Geng

3

1 reference

31 July 2017

Junjie Liu

4

1 reference

31 July 2017

Guisen Zhao

5

1 reference

31 July 2017

publication date

1 October 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

5

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

1651-1661

1 reference

Mechanisms mediating androgen receptor reactivation after castration

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

Bioisosterism: a useful strategy for molecular modification and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Chemistry and structural biology of androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Targeting the androgen receptor pathway in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A double nucleotide insertion-induced frame-shift mutation of the androgen receptor gene in a familial complete androgen insensitivity syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

The Role of Androgens in Normal and Malignant Breast Tissue

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Actin associated proteins function as androgen receptor coregulators: an implication of androgen receptor's roles in skeletal muscle

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structural basis for the nuclear import of the human androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

The steroid and thyroid hormone receptor superfamily

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Alterations of androgen receptor in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Molecular mechanisms of castration-resistant prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Secondary hormonal therapy for prostate cancer: what lies on the horizon?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Discovery of nonsteroidal androgens

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Recent advances in the development of selective androgen receptor modulators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Improving selective androgen receptor modulator discovery and preclinical evaluation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Circumventing anti-androgen resistance by molecular design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Thalidomide as a multi-template for development of biologically active compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

ENDOCRINE PROFILE OF A NONSTEROIDAL ANTIANDROGEN N-(3,5-DIMETHYL-4-ISOXAZOLYLMETHYL)PHTHALIMIDE (DIMP)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structural development of biological response modifiers based on retinoids and thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structural development of biological response modifiers based on thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Novel non-steroidal/non-anilide type androgen antagonists with an isoxazolone moiety

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A canonical structure for the ligand-binding domain of nuclear receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Computational approaches to structure-based ligand design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Potent androgen antagonists based on carborane as a hydrophobic core structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Acidic heterocycles as novel hydrophilic pharmacophore of androgen receptor ligands with a carborane core structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Thyroid receptor: roles in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

A surface on the androgen receptor that allosterically regulates coactivator binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Resveratrol--a prostate cancer chemopreventive agent?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Repressive effects of resveratrol on androgen receptor transcriptional activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Advances in prostate cancer chemotherapy: a new era begins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Progression of prostate cancer: multiple pathways to androgen independence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000259

7 January 2021

Identifiers

DOI

10.1002/CMDC.201000259

1 reference

31 July 2017

1 reference